GNLN vs RKDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GNLN exhibits extreme financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a total collapse in share price (-99.8% over 1 year). The company suffers from catastrophic operational inefficiency, evidenced by a negative gross margin of -286.22%, meaning it loses significant capital on every unit sold. Despite a high current ratio and zero debt, the business model is fundamentally broken with consistent quarterly losses over 17 consecutive periods and shrinking revenue. The stock is currently a value trap trading at a deep discount to book value but lacking any viable path to profitability.
RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.
Compare Another Pair
Related Comparisons
GNLN vs RKDA: Head-to-Head Comparison
This page compares Greenlane Holdings, Inc. (GNLN) and Arcadia Biosciences, Inc. (RKDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.